U.S. Patent No. 8,680,252 “Expression and High-Throughput Screening of Complex Expressed DNA in Filamentous Fungi”
JUPITER, Fla., March 27, 2014 – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,680,252 entitled, “Expression and High- Throughput Screening of Complex Expressed DNA in Filamentous Fungi” by the United States Patent and Trademark Office (“USPTO”).
This new patent provides methods for high-throughput screening of DNA libraries for commercially interesting genes. The ability to rapidly search for and identify novel genes allows for more effective and efficient development of new products. While this patent broadly covers various filamentous fungi, we believe that the physical characteristics of our C1 organism are exceptionally well-suited towards rapid screening, and protection of this process is therefore of particular significance to Dyadic.
Dr. Wim van der Wilden, General Manager of Dyadic Netherlands and Head of Dyadic R&D, stated, “High-throughput screening is an important process in developing new enzyme and other protein products. Sorting through large gene libraries can be a time consuming and tedious process. Traditional screening methods use one system to identify the genes and another to express or manufacture products from these genes. Methods described in this patent, which utilizes one system throughout the entire discovery, development, scale-up and manufacturing process, allows us to identify and bring to market better genes, more quickly and with a greater probability of success. Further, while these processes were originally designed for use with our proprietary C1 Expression System, we believe that they have the potential to be widely applied within our industry and this may be yet another opportunity to out-license our technology.”
This patent is the fifteenth U.S. patent issued to Dyadic adding to its portfolio of 41 international patents, 23 pending international and nine pending U.S. patent applications which cover various features of Dyadic’s proprietary technologies.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com. Dyadic trades on the OTCQX tier of the information and financial reports on OTC marketplace. Investors can find real-time quotes, market for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, our ability to efficiently develop new products, the potential wide applicability of our intellectual property and licensing opportunities, may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) whether the patented technology will result in any new products or improve our ability to efficiently and effectively develop new products; (2) whether the patented technology will result in any new customers, partners, collaborations or licensing agreements; (3) Dyadic’s research and development efforts, (4) Dyadic’s ability to successfully enforce its intellectual property rights and (5) other factors discussed in Dyadic’s publicly available filings, including the risk factors included in Dyadic’s Initial Information and Disclosure Statement filed with the OTC Markets Group on March 11, 2014.
Investor Relations Contact:
Dyadic International, Inc.
Michael J. Faby
Vice President and Chief Financial Officer